You are here: Industry Insights > plaque psoriasis

News List

FDA Approves Otezla (apremilast) for the Treatment of Adult Patients with Plaque Psoriasis, Regardless of Severity Level Drugs
December 27, 2021
Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.
UCB’s BIMZELX (bimekizumab) receives expedited acceptance from Scottish Medicines Consortium (SMC) for the treatment of plaque psoriasis FirstWordPharma
November 10, 2021
Bimekizumab has received acceptance through the Scottish Medicines Consortium’s (SMC) fast- track process1
NICE approves cost-comparison fast-track appraisal pilot europeanpharmaceuticalreview
August 03, 2021
A new approach to the cost-comparison fast-track appraisal process is being piloted this summer for the review of low-risk appraisals.
UCB’s bimekizumab issued NICE recommendation for severe plaque psoriasis pharmatimes
August 03, 2021
The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD), recommending UCB’s bimekizumab as an option for the treatment of adults with severe plaque psoriasis.
CHMP recommends approval of UCB’s Bimzelx for plaque psoriasis pharmatimes
June 29, 2021
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval for UCB’s Bimzelx as a treatment for moderate-to-severe plaque psoriasis.
FDA Approves Novartis Cosentyx for Children with Plaque Psoriasis americanpharmaceuticalreview
June 04, 2021
Novartis, a leader in immuno-dermatology and rheumatology, announced that the FDA has approved Cosentyx® (secukinumab) for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for systemic ...
Cosentyx approved to treat plaque psoriasis in paediatric patients pharmatimes
June 03, 2021
The US Food and Drug Administration (FDA) has approved Novartis’ interleukin-17A (IL-17A) inhibitor Cosentyx for the treatment of children and adolescents with moderate to severe plaque psoriasis.
Amgen looks to expand access to Otezla in the US pharmatimes
February 24, 2021
Amgen has submitted a supplemental new drug application (sNDA) seeking expanded approval for Otezla in adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy.
UCB’s bimekizumab data in plaque psoriasis published in The Lancet pharmatimes
February 05, 2021
Data from two Phase III studies of UCB’s investigational treatment bimekizumab in moderate-to-severe plaque psoriasis have been published in The Lancet.
Sun Pharma starts Phase II trial of SCD-044 for moderate to severe plaque psoriasis expresspharma
January 05, 2021
SCD-044 is also being evaluated in other autoimmune disorders and Phase 2 studies for other indications like atopic dermatitis, are also expected to be initiated soon, informed the company.

Previous page 1 2 3 4 Next page